Top Markets
Coin of the day
RegeneRx Biopharmaceuticals, Inc. RegeneRx Biopharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc.

RGRX
Pozycja w akcjach #42502
RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the... RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.
Cena akcji
$0.0007
Ostatnia synchronizacja: 2026-08-11
Kapitalizacja rynkowa
$1.05K
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
250.00%
Kraj
US
Handel RegeneRx Biopharmaceuticals, Inc. (RGRX)

Kategoria

EPS dla RegeneRx Biopharmaceuticals, Inc. (RGRX)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy RegeneRx Biopharmaceuticals, Inc., obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla RegeneRx Biopharmaceuticals, Inc. od 2026 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
Za mało danych dla podanych dat.
EPS dla podobnych firm lub konkurentów